70 results
8-K
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained
8-K
EX-10.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
.
(h) Litigation. There is no action, suit, proceeding or investigation pending or, to the Knowledge of the Company, threatened (including “cease … shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
8-K
EX-99.1
94n9k5wl6aaeixrwhsg
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
8jr7cpn
4 Jan 24
Entry into a Material Definitive Agreement
7:00am
8-K
fj61jrn
6 Dec 23
Other Events
4:30pm
8-K
EX-99.1
i5c3h0rtzcti1 umtg
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
hgjzf8gctu
21 Aug 23
Other Events
4:30pm
8-K
EX-99.1
60nlj6v cuxssk
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
q4y85rvkz02 xlf54y5
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
5kwqhxlp 6xb
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
8-K
padvdt6yunk9pnuk16y
3 Nov 22
Termination of a Material Definitive Agreement
4:55pm